Coffee Consumption Is Associated With Response to Peginterferon and Ribavirin Therapy in Patients With Chronic Hepatitis C

[Guest guest]

http://www.gastrojournal.org/article/PIIS0016508511002733/abstract?rss=yes

Coffee Consumption Is Associated With Response to Peginterferon and Ribavirin

Therapy in Patients With Chronic Hepatitis C

Neal D. Freedman, M. Curto, L. , C. , Rashmi

Sinha, E. Everhart, HALT-C TRIAL GROUP

Received 20 November 2010; accepted 18 February 2011. published online 03 March

2011.

ABSTRACT

Background & Aims

High-level coffee consumption has been associated with reduced progression of

pre-existing liver diseases and lower risk of hepatocellular carcinoma. However,

its relationship with therapy for hepatitis C virus infection has not been

evaluated.

Methods

Patients (n = 885) from the lead-in phase of the Hepatitis C Antiviral Long-Term

Treatment Against Cirrhosis Trial recorded coffee intake before retreatment with

peginterferon á-2a (180 ìg/wk) and ribavirin (1000-1200 mg/day). We assessed

patients for early virologic response (2 log10 reduction in level of hepatitis C

virus RNA at week 12; n = 466), and undetectable hepatitis C virus RNA at weeks

20 (n = 320), 48 (end of treatment, n = 284), and 72 (sustained virologic

response; n = 157).

Results

Median log10 drop from baseline to week 20 was 2.0 (interquartile range [iQR],

0.6-3.9) among nondrinkers and 4.0 (IQR, 2.1-4.7) among patients that drank 3 or

more cups/day of coffee (P trend <.0001). After adjustment for age,

race/ethnicity, sex, alcohol, cirrhosis, ratio of aspartate aminotransferase to

alanine aminotransferase, the IL28B polymorphism rs12979860, dose reduction of

peginterferon, and other covariates, odds ratios for drinking 3 or more cups/day

vs nondrinking were 2.0 (95% confidence interval [CI]: 1.1-3.6; P trend = .004)

for early virologic response, 2.1 (95% CI: 1.1-3.9; P trend = .005) for week 20

virologic response, 2.4 (95% CI: 1.3-4.6; P trend = .001) for end of treatment,

and 1.8 (95% CI: 0.8-3.9; P trend = .034) for sustained virologic response.

Conclusions

High-level consumption of coffee (more than 3 cups per day) is an independent

predictor of improved virologic response to peginterferon plus ribavirin in

patients with hepatitis C.

[Guest guest]

http://www.gastrojournal.org/article/PIIS0016508511002733/abstract?rss=yes

Coffee Consumption Is Associated With Response to Peginterferon and Ribavirin

Therapy in Patients With Chronic Hepatitis C

Neal D. Freedman, M. Curto, L. , C. , Rashmi

Sinha, E. Everhart, HALT-C TRIAL GROUP

Received 20 November 2010; accepted 18 February 2011. published online 03 March

2011.

ABSTRACT

Background & Aims

High-level coffee consumption has been associated with reduced progression of

pre-existing liver diseases and lower risk of hepatocellular carcinoma. However,

its relationship with therapy for hepatitis C virus infection has not been

evaluated.

Methods

Patients (n = 885) from the lead-in phase of the Hepatitis C Antiviral Long-Term

Treatment Against Cirrhosis Trial recorded coffee intake before retreatment with

peginterferon á-2a (180 ìg/wk) and ribavirin (1000-1200 mg/day). We assessed

patients for early virologic response (2 log10 reduction in level of hepatitis C

virus RNA at week 12; n = 466), and undetectable hepatitis C virus RNA at weeks

20 (n = 320), 48 (end of treatment, n = 284), and 72 (sustained virologic

response; n = 157).

Results

Median log10 drop from baseline to week 20 was 2.0 (interquartile range [iQR],

0.6-3.9) among nondrinkers and 4.0 (IQR, 2.1-4.7) among patients that drank 3 or

more cups/day of coffee (P trend <.0001). After adjustment for age,

race/ethnicity, sex, alcohol, cirrhosis, ratio of aspartate aminotransferase to

alanine aminotransferase, the IL28B polymorphism rs12979860, dose reduction of

peginterferon, and other covariates, odds ratios for drinking 3 or more cups/day

vs nondrinking were 2.0 (95% confidence interval [CI]: 1.1-3.6; P trend = .004)

for early virologic response, 2.1 (95% CI: 1.1-3.9; P trend = .005) for week 20

virologic response, 2.4 (95% CI: 1.3-4.6; P trend = .001) for end of treatment,

and 1.8 (95% CI: 0.8-3.9; P trend = .034) for sustained virologic response.

Conclusions

High-level consumption of coffee (more than 3 cups per day) is an independent

predictor of improved virologic response to peginterferon plus ribavirin in

patients with hepatitis C.

[Guest guest]

http://www.gastrojournal.org/article/PIIS0016508511002733/abstract?rss=yes

Coffee Consumption Is Associated With Response to Peginterferon and Ribavirin

Therapy in Patients With Chronic Hepatitis C

Neal D. Freedman, M. Curto, L. , C. , Rashmi

Sinha, E. Everhart, HALT-C TRIAL GROUP

Received 20 November 2010; accepted 18 February 2011. published online 03 March

2011.

ABSTRACT

Background & Aims

High-level coffee consumption has been associated with reduced progression of

pre-existing liver diseases and lower risk of hepatocellular carcinoma. However,

its relationship with therapy for hepatitis C virus infection has not been

evaluated.

Methods

Patients (n = 885) from the lead-in phase of the Hepatitis C Antiviral Long-Term

Treatment Against Cirrhosis Trial recorded coffee intake before retreatment with

peginterferon á-2a (180 ìg/wk) and ribavirin (1000-1200 mg/day). We assessed

patients for early virologic response (2 log10 reduction in level of hepatitis C

virus RNA at week 12; n = 466), and undetectable hepatitis C virus RNA at weeks

20 (n = 320), 48 (end of treatment, n = 284), and 72 (sustained virologic

response; n = 157).

Results

Median log10 drop from baseline to week 20 was 2.0 (interquartile range [iQR],

0.6-3.9) among nondrinkers and 4.0 (IQR, 2.1-4.7) among patients that drank 3 or

more cups/day of coffee (P trend <.0001). After adjustment for age,

race/ethnicity, sex, alcohol, cirrhosis, ratio of aspartate aminotransferase to

alanine aminotransferase, the IL28B polymorphism rs12979860, dose reduction of

peginterferon, and other covariates, odds ratios for drinking 3 or more cups/day

vs nondrinking were 2.0 (95% confidence interval [CI]: 1.1-3.6; P trend = .004)

for early virologic response, 2.1 (95% CI: 1.1-3.9; P trend = .005) for week 20

virologic response, 2.4 (95% CI: 1.3-4.6; P trend = .001) for end of treatment,

and 1.8 (95% CI: 0.8-3.9; P trend = .034) for sustained virologic response.

Conclusions

High-level consumption of coffee (more than 3 cups per day) is an independent

predictor of improved virologic response to peginterferon plus ribavirin in

patients with hepatitis C.

[Guest guest]

http://www.gastrojournal.org/article/PIIS0016508511002733/abstract?rss=yes

Coffee Consumption Is Associated With Response to Peginterferon and Ribavirin

Therapy in Patients With Chronic Hepatitis C

Neal D. Freedman, M. Curto, L. , C. , Rashmi

Sinha, E. Everhart, HALT-C TRIAL GROUP

Received 20 November 2010; accepted 18 February 2011. published online 03 March

2011.

ABSTRACT

Background & Aims

High-level coffee consumption has been associated with reduced progression of

pre-existing liver diseases and lower risk of hepatocellular carcinoma. However,

its relationship with therapy for hepatitis C virus infection has not been

evaluated.

Methods

Patients (n = 885) from the lead-in phase of the Hepatitis C Antiviral Long-Term

Treatment Against Cirrhosis Trial recorded coffee intake before retreatment with

peginterferon á-2a (180 ìg/wk) and ribavirin (1000-1200 mg/day). We assessed

patients for early virologic response (2 log10 reduction in level of hepatitis C

virus RNA at week 12; n = 466), and undetectable hepatitis C virus RNA at weeks

20 (n = 320), 48 (end of treatment, n = 284), and 72 (sustained virologic

response; n = 157).

Results

Median log10 drop from baseline to week 20 was 2.0 (interquartile range [iQR],

0.6-3.9) among nondrinkers and 4.0 (IQR, 2.1-4.7) among patients that drank 3 or

more cups/day of coffee (P trend <.0001). After adjustment for age,

race/ethnicity, sex, alcohol, cirrhosis, ratio of aspartate aminotransferase to

alanine aminotransferase, the IL28B polymorphism rs12979860, dose reduction of

peginterferon, and other covariates, odds ratios for drinking 3 or more cups/day

vs nondrinking were 2.0 (95% confidence interval [CI]: 1.1-3.6; P trend = .004)

for early virologic response, 2.1 (95% CI: 1.1-3.9; P trend = .005) for week 20

virologic response, 2.4 (95% CI: 1.3-4.6; P trend = .001) for end of treatment,

and 1.8 (95% CI: 0.8-3.9; P trend = .034) for sustained virologic response.

Conclusions

High-level consumption of coffee (more than 3 cups per day) is an independent

predictor of improved virologic response to peginterferon plus ribavirin in

patients with hepatitis C.